Janux Therapeutics (JANX) Change in Account Payables (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Change in Account Payables data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 1.53% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was $1.0 million, a 148.64% increase from a year earlier, with the FY2025 full-year figure at $977000.0, down 38.32% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$1.6 million, down from $1.7 million in the prior quarter.
• Over the last five years, Change in Account Payables for JANX reached as high as $1.7 million in Q4 2025 and fell as low as -$1.6 million in Q1 2025.
• Historically, Change in Account Payables has averaged $54823.5 across 5 years, with a median of -$107000.0 in 2023.
• On a YoY basis, Change in Account Payables climbed as much as 415.35% in 2024 and fell as far as 326.17% in 2024.
• Year by year, Change in Account Payables stood at $223000.0 in 2022, then soared by 46.64% to $327000.0 in 2023, then jumped by 376.76% to $1.6 million in 2024, then grew by 7.06% to $1.7 million in 2025, then slumped by 196.58% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$1.6 million in Q1 2026, $1.7 million in Q4 2025, and -$168000.0 in Q3 2025.